...
首页> 外文期刊>Toxicon: An International Journal Devoted to the Exchange of Knowledge on the Poisons Derived from Animals, Plants and Microorganisms >G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors
【24h】

G protein-coupled receptors, an unexploited animal toxin targets: Exploration of green mamba venom for novel drug candidates active against adrenoceptors

机译:G蛋白偶联受体,一种未利用的动物毒素靶标:探索绿色曼巴蛇毒,寻找对肾上腺素受体具有活性的新型药物

获取原文
获取原文并翻译 | 示例
           

摘要

At a time when pharmaceutical companies are having trouble finding new low MW drugs and when biologics are becoming more common, animal venoms could constitute an underexploited source of novel drug candidates. We looked for identifying novel animal toxins active against G protein-coupled receptors (GPCR), the most frequently exploited class of treatment targets, with the aim to develop novel research tools and drug candidates. Screening of green mamba (Dendroaspis angusticeps) venom against adrenoceptors identified two novel venom peptides. rho-Da1a shown an affinity of 0.35 nM for the alpha 1a-AR while rho-Da1b displayed affinities between 14 and 73 nM for the three alpha 2-ARs. These two venom peptides have sequences similar to those of muscarinic toxins and belong to the three-finger-fold protein family. alpha 1a-AR is the primary target for the treatment of prostate hypertrophy. In vitro and in vivo tests demonstrated that rho-Da1a reduced prostatic muscle tone as efficiently as tamsulosin (an antagonist presently used), but with fewer cardiovascular side effects. alpha 2-ARs are the prototype of GPCRs not currently used as treatment targets due to a lack of specific ligands. Blockage of these receptors increases intestinal motility, which may be compromised by abdominal surgery and reduces orthosteric hypotension. In vitro and in vivo tests demonstrated that rho-Da1b antagonizes alpha 2-ARs in smooth muscles and increased heart rate and blood catecholamine concentrations. These results highlight possible exploitation of rho-Da1a and rho-Da1b in important pathologies. (C) 2011 Elsevier Ltd. All rights reserved.
机译:当制药公司在寻找新的低分子量药物时遇到困难,而生物制剂变得越来越普遍时,动物毒液可能构成了未被充分利用的新型候选药物的来源。我们寻求鉴定对G蛋白偶联受体(GPCR)有活性的新型动物毒素,这是最常被利用的一类治疗靶标,目的是开发新型研究工具和候选药物。针对肾上腺素能受体的绿色曼巴蛇毒(Dendroaspis angusticeps)的筛选确定了两种新的毒肽。 rho-Da1a对alpha 1a-AR的亲和力为0.35 nM,而rho-Da1b对3个alpha 2-ARs的亲和力为14至73 nM。这两个毒液肽的序列与毒蕈碱毒素的序列相似,属于三指折叠蛋白家族。 α1a-AR是治疗前列腺肥大的主要靶标。体外和体内试验表明,rho-Da1a与坦洛新(目前使用的拮抗剂)一样有效地降低了前列腺肌张力,但心血管副作用较小。 α2-AR是GPCR的原型,由于缺乏特异性配体,目前尚未用作治疗靶标。这些受体的阻塞会增加肠蠕动,可能会因腹部手术而受损并降低正位性低血压。体外和体内试验表明,rho-Da1b拮抗平滑肌中的α2-AR,并增加了心率和血液中的儿茶酚胺浓度。这些结果突出了在重要病理中可能对rho-Da1a和rho-Da1b的利用。 (C)2011 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号